JP2007515469A5 - - Google Patents

Download PDF

Info

Publication number
JP2007515469A5
JP2007515469A5 JP2006546357A JP2006546357A JP2007515469A5 JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5 JP 2006546357 A JP2006546357 A JP 2006546357A JP 2006546357 A JP2006546357 A JP 2006546357A JP 2007515469 A5 JP2007515469 A5 JP 2007515469A5
Authority
JP
Japan
Prior art keywords
antibody
use according
patient
group
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/004103 external-priority patent/WO2005063289A1/en
Publication of JP2007515469A publication Critical patent/JP2007515469A/ja
Publication of JP2007515469A5 publication Critical patent/JP2007515469A5/ja
Pending legal-status Critical Current

Links

JP2006546357A 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法 Pending JP2007515469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
PCT/IB2004/004103 WO2005063289A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011100868A Division JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法

Publications (2)

Publication Number Publication Date
JP2007515469A JP2007515469A (ja) 2007-06-14
JP2007515469A5 true JP2007515469A5 (enExample) 2008-01-31

Family

ID=34738672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006546357A Pending JP2007515469A (ja) 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Country Status (20)

Country Link
US (4) US20050136055A1 (enExample)
EP (3) EP2218461B1 (enExample)
JP (3) JP2007515469A (enExample)
KR (2) KR100847944B1 (enExample)
CN (2) CN1897971A (enExample)
AU (1) AU2004308749B2 (enExample)
BR (1) BRPI0418029B8 (enExample)
CA (2) CA2549652C (enExample)
DK (1) DK2218461T3 (enExample)
ES (1) ES2580002T3 (enExample)
HU (1) HUE027717T2 (enExample)
IL (2) IL175540A (enExample)
NO (1) NO343797B1 (enExample)
NZ (2) NZ547162A (enExample)
PL (1) PL2218461T3 (enExample)
RU (1) RU2355421C2 (enExample)
SI (1) SI2218461T1 (enExample)
TW (1) TWI359671B (enExample)
WO (1) WO2005063289A1 (enExample)
ZA (1) ZA200603804B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
EP2019857B1 (en) * 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
EP2702078B1 (en) 2011-04-29 2018-11-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
PL3444271T3 (pl) 2013-08-08 2022-03-07 Cytune Pharma Modulokiny oparte na il-15 i domenie sushi il-15ralfa
SI3212230T1 (sl) 2014-10-29 2021-08-31 Seagen Inc. Doziranje in dajanje ne-fukoziliranih protiteles proti-CD40
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018085734A1 (en) 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
KR102198998B1 (ko) * 2017-06-01 2021-01-07 서울대학교 산학협력단 신규한 항-ｃｄ40 항체 및 이의 용도
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
TW201902462A (zh) * 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
AU2019349874A1 (en) * 2018-09-28 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
KR20210070317A (ko) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도
CN112839961B (zh) * 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
US12435150B2 (en) 2019-01-11 2025-10-07 Novartis Ag Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN119264273A (zh) 2019-12-03 2025-01-07 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3185616A1 (en) * 2020-06-04 2021-12-09 Selvax Pty Ltd Agonist anti-cd40 antibodies
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
WO2022037662A1 (en) * 2020-08-21 2022-02-24 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
ATE255906T1 (de) * 1993-10-01 2003-12-15 Immunex Corp Antikörper gegen cd40
ATE267607T1 (de) * 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
DK2314315T3 (en) * 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
EP1975182A1 (en) 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002028481A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
ATE556591T1 (de) * 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005512044A (ja) * 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Similar Documents

Publication Publication Date Title
JP2007515469A5 (enExample)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2012067116A5 (enExample)
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
JP2005515966A5 (enExample)
CN109562281B (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2008507536A5 (enExample)
WO2010081817A1 (en) Method for treating colorectal cancer
JP2006513184A5 (enExample)
KR20240056564A (ko) T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도
CN108367001A (zh) 治疗丁型肝炎病毒感染
JP2005506345A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2006514681A5 (enExample)
JP2004525143A5 (enExample)
JP2024016209A5 (enExample)
JP2007504268A5 (enExample)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
CN117940128A (zh) 异丁司特用于防止眼癌转移
JP2005508323A5 (enExample)
WO2024120523A1 (zh) 一种治疗前列腺癌的药物组合及其应用
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
CN102781238A (zh) Tivozanib和坦罗莫司的组合